Thursday, May 18, 2017 8:11:39 AM
CYTR - .4533 Pre-market now at .485/.489
BZ: CytRx Says Results from Phase 3 Aldoxorubicin Data in Patients with Soft Tissue Sarcomas 'Continue to Demonstrate Significantly Prolonged PFS in North American and L-sarcoma Patients Compared to Standard Treatments'
BZ: CytRx Says Results from Phase 3 Aldoxorubicin Data in Patients with Soft Tissue Sarcomas 'Continue to Demonstrate Significantly Prolonged PFS in North American and L-sarcoma Patients Compared to Standard Treatments'
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
